Novartis' Cosentyx Receives FDA Approval for Pediatric Use
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2024
0mins
Source: MarketWatch
Novartis AG's stock has hit a 20-day low amid a broader market decline, with the Nasdaq-100 down 1.03% and the S&P 500 down 1.06%.
The company's Cosentyx has received FDA approval as the first IL-17A inhibitor for pediatric patients aged 12 and older with moderate to severe hidradenitis suppurativa, addressing a significant gap in care. This approval is expected to enhance the quality of life for affected adolescents and is projected to generate $6.7 billion in sales for 2025, reflecting sustained growth potential in the immunology sector.
The approval of Cosentyx is a significant milestone for Novartis, as it not only expands the drug's market but also demonstrates the company's commitment to addressing unmet medical needs. However, the stock's current decline highlights the challenges it faces in a weak market environment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVS
Wall Street analysts forecast NVS stock price to fall
6 Analyst Rating
1 Buy
4 Hold
1 Sell
Hold
Current: 150.880
Low
112.00
Averages
127.75
High
143.00
Current: 150.880
Low
112.00
Averages
127.75
High
143.00
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Swiss Voters Likely to Reject Stronger Neutrality Proposal
- Poll Predictions: An early Tamedia poll indicates that 54% of Swiss voters are likely or definitely against the proposal to strengthen neutrality, reflecting widespread resistance that could influence future foreign policy directions.
- Proposal Background: The initiative aims to enshrine permanent neutrality in Switzerland's constitution and prohibit economic sanctions against nations involved in armed conflicts, showcasing strong support from the Swiss People's Party (SVP) but facing opposition from the government and parliament.
- Political Reactions: Since Russia's invasion of Ukraine, the neutrality debate has gained significant attention, with officials arguing for flexibility in neutrality policy to better respond to international conflicts and sanctions, highlighting potential impacts on future government decisions.
- Future Outlook: If current polling trends hold, Switzerland would maintain its existing interpretation of neutrality, allowing greater flexibility for the government in international conflicts and sanctions regimes, while immigration and EU relations are expected to remain major political themes in the coming years.
See More
Analysis of International Stock Investment Opportunities
- Valuation Gap: Over the past decade, the S&P 500 has returned approximately 314%, while the Vanguard Total International Stock ETF has only achieved 145%, indicating a significant valuation gap that may present a compelling entry point for investors.
- ETF Investment Benefits: The Vanguard Total International Stock ETF boasts over 8,700 stocks across developed and emerging markets, with an expense ratio of just 0.05%, meaning investors pay only $0.50 annually for every $1,000 invested, greatly reducing investment costs.
- Market Performance Comparison: The average price-to-book ratio for S&P 500 stocks is 5.5 times, while the international ETF averages just 2.3 times, highlighting the relative affordability of international stocks, which may attract value-seeking investors.
- Future Investment Confidence: Although international stocks have underperformed over the past decade, the risk-reward dynamics of investing in the Vanguard Total International Stock ETF appear more attractive in today's overvalued market, with expectations for better returns by 2026.
See More
Vanguard Total International Stock ETF Valuation Gap Widens
- Underperformance of International Stocks: Over the past decade, international stocks have significantly underperformed U.S. stocks, with the S&P 500 generating total returns of approximately 314% compared to just 145% for the Vanguard Total International Stock ETF, indicating potential undervaluation in the international market.
- Widening Valuation Gap: The average price-to-book ratio for the S&P 500 is about 5.5 times, while the international ETF trades at just 2.3 times, highlighting a significant valuation disparity that could present an attractive opportunity for investors.
- Low Expense Advantage: The Vanguard Total International Stock ETF boasts a rock-bottom expense ratio of only 0.05%, meaning investors pay just $0.50 annually for every $1,000 invested, making it an ideal choice for low-cost exposure to international markets.
- Future Investment Potential: Despite the underperformance of international stocks over the past decade, the risk-reward dynamics of investing in a broad international ETF may be more appealing in today's high-valuation market environment, especially for those seeking portfolio diversification.
See More
Teva Pharmaceuticals Transitions to Innovative Drug Development
- Innovative Drug Growth: Teva Pharmaceuticals reported $4 billion in revenue for Q1 2026, a 2% year-over-year increase, with innovative brands like Austedo, Ajovy, and Uzedy growing revenue by 41%, indicating successful transformation and potential for increased market share.
- Clinical Research Outcomes: At the Psych Congress Elevate, Teva revealed that over 50% of tardive dyskinesia patients showed symptom improvement within 15 weeks, suggesting that Austedo XR may expand its use for Huntington's disease, bolstering physician prescribing confidence.
- Financial Health: The company anticipates free cash flow of $2 billion to $2.4 billion in 2026, aiding in debt reduction, while its non-GAAP gross profit margin rose to 52.9% in Q1, reflecting enhanced profitability.
- Market Challenges and Outlook: Despite projecting total revenue of $16.4 billion to $16.8 billion for 2026, indicating flat or slightly negative growth, Teva's innovative drugs target unmet medical needs, positioning the company for future growth through its new drug pipeline.
See More
Teva Pharmaceuticals Reports Strong Q1 Performance
- Profitability Surge: Teva Pharmaceuticals reported a 72% year-over-year increase in EPS for Q1, reaching $0.31, indicating success in its transformation into an innovative drug developer, despite market disappointment regarding its annual guidance.
- Innovative Drug Performance: Research on Austedo and Austedo XR revealed that over 50% of tardive dyskinesia patients experienced symptom improvement within 15 weeks, enhancing Teva's position in a competitive market and expected to drive future market share growth.
- Financial Health: The company anticipates generating free cash flow between $2 billion and $2.4 billion in 2026, primarily to pay down its heavy debt load, while achieving a gross profit margin of 52.9% in Q1, despite fierce competition from generics.
- Market Challenges: Teva's revenue guidance for 2026 is set at $16.4 billion to $16.8 billion, indicating flat to slightly negative growth expectations, primarily due to generic competition and a decline in one-time milestone payments, which may limit short-term stock price upside.
See More
U.S. Launches Investigation into Germany's Pharma Policies
- Drug Price Investigation: The U.S. has initiated an investigation into Germany's pharmaceutical policies due to what it describes as 'persistent underpayment,' raising concerns about potential negative impacts on the U.S. drug market.
- Legislative Acceleration: Germany is fast-tracking legislation aimed at reducing spending on innovative pharmaceuticals, a move that has drawn strong opposition from U.S. trade representatives who argue it undermines global fairness in drug development.
- Cost-Cutting Measures: The proposed cost-saving measures in Germany, including increased discounts from the pharmaceutical industry to insurance funds, have prompted warnings from drugmakers about possible withdrawal or delays in launching new medicines, affecting market competitiveness.
- Call for International Negotiations: The U.S. Trade Representative has urged Germany to address drug price imbalances through constructive negotiations, emphasizing that agreements with other countries can avoid legal actions, highlighting the importance of international cooperation.
See More
Swiss Voters Likely to Reject Stronger Neutrality Proposal
- Poll Predictions: An early Tamedia poll indicates that 54% of Swiss voters are likely or definitely against the proposal to strengthen neutrality, reflecting widespread resistance that could influence future foreign policy directions.
- Proposal Background: The initiative aims to enshrine permanent neutrality in Switzerland's constitution and prohibit economic sanctions against nations involved in armed conflicts, showcasing strong support from the Swiss People's Party (SVP) but facing opposition from the government and parliament.
- Political Reactions: Since Russia's invasion of Ukraine, the neutrality debate has gained significant attention, with officials arguing for flexibility in neutrality policy to better respond to international conflicts and sanctions, highlighting potential impacts on future government decisions.
- Future Outlook: If current polling trends hold, Switzerland would maintain its existing interpretation of neutrality, allowing greater flexibility for the government in international conflicts and sanctions regimes, while immigration and EU relations are expected to remain major political themes in the coming years.
See More
Analysis of International Stock Investment Opportunities
- Valuation Gap: Over the past decade, the S&P 500 has returned approximately 314%, while the Vanguard Total International Stock ETF has only achieved 145%, indicating a significant valuation gap that may present a compelling entry point for investors.
- ETF Investment Benefits: The Vanguard Total International Stock ETF boasts over 8,700 stocks across developed and emerging markets, with an expense ratio of just 0.05%, meaning investors pay only $0.50 annually for every $1,000 invested, greatly reducing investment costs.
- Market Performance Comparison: The average price-to-book ratio for S&P 500 stocks is 5.5 times, while the international ETF averages just 2.3 times, highlighting the relative affordability of international stocks, which may attract value-seeking investors.
- Future Investment Confidence: Although international stocks have underperformed over the past decade, the risk-reward dynamics of investing in the Vanguard Total International Stock ETF appear more attractive in today's overvalued market, with expectations for better returns by 2026.
See More
Vanguard Total International Stock ETF Valuation Gap Widens
- Underperformance of International Stocks: Over the past decade, international stocks have significantly underperformed U.S. stocks, with the S&P 500 generating total returns of approximately 314% compared to just 145% for the Vanguard Total International Stock ETF, indicating potential undervaluation in the international market.
- Widening Valuation Gap: The average price-to-book ratio for the S&P 500 is about 5.5 times, while the international ETF trades at just 2.3 times, highlighting a significant valuation disparity that could present an attractive opportunity for investors.
- Low Expense Advantage: The Vanguard Total International Stock ETF boasts a rock-bottom expense ratio of only 0.05%, meaning investors pay just $0.50 annually for every $1,000 invested, making it an ideal choice for low-cost exposure to international markets.
- Future Investment Potential: Despite the underperformance of international stocks over the past decade, the risk-reward dynamics of investing in a broad international ETF may be more appealing in today's high-valuation market environment, especially for those seeking portfolio diversification.
See More
Teva Pharmaceuticals Transitions to Innovative Drug Development
- Innovative Drug Growth: Teva Pharmaceuticals reported $4 billion in revenue for Q1 2026, a 2% year-over-year increase, with innovative brands like Austedo, Ajovy, and Uzedy growing revenue by 41%, indicating successful transformation and potential for increased market share.
- Clinical Research Outcomes: At the Psych Congress Elevate, Teva revealed that over 50% of tardive dyskinesia patients showed symptom improvement within 15 weeks, suggesting that Austedo XR may expand its use for Huntington's disease, bolstering physician prescribing confidence.
- Financial Health: The company anticipates free cash flow of $2 billion to $2.4 billion in 2026, aiding in debt reduction, while its non-GAAP gross profit margin rose to 52.9% in Q1, reflecting enhanced profitability.
- Market Challenges and Outlook: Despite projecting total revenue of $16.4 billion to $16.8 billion for 2026, indicating flat or slightly negative growth, Teva's innovative drugs target unmet medical needs, positioning the company for future growth through its new drug pipeline.
See More
Teva Pharmaceuticals Reports Strong Q1 Performance
- Profitability Surge: Teva Pharmaceuticals reported a 72% year-over-year increase in EPS for Q1, reaching $0.31, indicating success in its transformation into an innovative drug developer, despite market disappointment regarding its annual guidance.
- Innovative Drug Performance: Research on Austedo and Austedo XR revealed that over 50% of tardive dyskinesia patients experienced symptom improvement within 15 weeks, enhancing Teva's position in a competitive market and expected to drive future market share growth.
- Financial Health: The company anticipates generating free cash flow between $2 billion and $2.4 billion in 2026, primarily to pay down its heavy debt load, while achieving a gross profit margin of 52.9% in Q1, despite fierce competition from generics.
- Market Challenges: Teva's revenue guidance for 2026 is set at $16.4 billion to $16.8 billion, indicating flat to slightly negative growth expectations, primarily due to generic competition and a decline in one-time milestone payments, which may limit short-term stock price upside.
See More
U.S. Launches Investigation into Germany's Pharma Policies
- Drug Price Investigation: The U.S. has initiated an investigation into Germany's pharmaceutical policies due to what it describes as 'persistent underpayment,' raising concerns about potential negative impacts on the U.S. drug market.
- Legislative Acceleration: Germany is fast-tracking legislation aimed at reducing spending on innovative pharmaceuticals, a move that has drawn strong opposition from U.S. trade representatives who argue it undermines global fairness in drug development.
- Cost-Cutting Measures: The proposed cost-saving measures in Germany, including increased discounts from the pharmaceutical industry to insurance funds, have prompted warnings from drugmakers about possible withdrawal or delays in launching new medicines, affecting market competitiveness.
- Call for International Negotiations: The U.S. Trade Representative has urged Germany to address drug price imbalances through constructive negotiations, emphasizing that agreements with other countries can avoid legal actions, highlighting the importance of international cooperation.
See More
